McKesson (MCK) Expected to Announce Quarterly Earnings on Wednesday

McKesson (NYSE:MCK - Get Free Report) is anticipated to issue its quarterly earnings data after the market closes on Wednesday, February 5th. Analysts expect the company to announce earnings of $8.60 per share and revenue of $95.86 billion for the quarter. Parties interested in listening to the company's conference call can do so using this link.

McKesson (NYSE:MCK - Get Free Report) last posted its earnings results on Wednesday, November 6th. The company reported $7.07 earnings per share (EPS) for the quarter, beating analysts' consensus estimates of $6.88 by $0.19. The firm had revenue of $93.65 billion during the quarter, compared to analysts' expectations of $89.33 billion. McKesson had a net margin of 0.77% and a negative return on equity of 207.50%. The company's revenue was up 21.3% compared to the same quarter last year. During the same period in the previous year, the company earned $6.23 earnings per share. On average, analysts expect McKesson to post $33 EPS for the current fiscal year and $37 EPS for the next fiscal year.

McKesson Trading Down 1.6 %

NYSE MCK traded down $9.75 during trading on Friday, reaching $594.85. The company's stock had a trading volume of 786,879 shares, compared to its average volume of 659,902. The business has a 50-day moving average price of $591.35 and a 200-day moving average price of $562.12. McKesson has a 1-year low of $464.42 and a 1-year high of $637.51. The stock has a market capitalization of $75.51 billion, a PE ratio of 30.81, a PEG ratio of 1.30 and a beta of 0.52.

McKesson Announces Dividend

The company also recently disclosed a quarterly dividend, which will be paid on Tuesday, April 1st. Stockholders of record on Monday, March 3rd will be paid a $0.71 dividend. This represents a $2.84 dividend on an annualized basis and a dividend yield of 0.48%. The ex-dividend date of this dividend is Monday, March 3rd. McKesson's payout ratio is 14.71%.

Insider Buying and Selling at McKesson

In other news, EVP Leann B. Smith sold 579 shares of the company's stock in a transaction dated Thursday, January 2nd. The shares were sold at an average price of $572.79, for a total value of $331,645.41. Following the sale, the executive vice president now owns 864 shares of the company's stock, valued at approximately $494,890.56. This represents a 40.12 % decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. Insiders own 0.11% of the company's stock.

Analyst Upgrades and Downgrades

A number of brokerages have recently weighed in on MCK. Robert W. Baird upgraded shares of McKesson from a "neutral" rating to an "outperform" rating and boosted their price objective for the stock from $531.00 to $688.00 in a research note on Thursday, November 7th. Evercore ISI boosted their price objective on shares of McKesson from $560.00 to $680.00 and gave the stock an "outperform" rating in a research note on Thursday, November 7th. Baird R W upgraded shares of McKesson from a "hold" rating to a "strong-buy" rating in a research note on Thursday, November 7th. Mizuho initiated coverage on shares of McKesson in a research note on Wednesday, December 4th. They issued a "neutral" rating and a $630.00 price objective for the company. Finally, Morgan Stanley boosted their target price on shares of McKesson from $612.00 to $642.00 and gave the stock an "overweight" rating in a research report on Tuesday, December 17th. Two equities research analysts have rated the stock with a hold rating, fourteen have issued a buy rating and one has assigned a strong buy rating to the company. According to data from MarketBeat, McKesson has a consensus rating of "Moderate Buy" and a consensus price target of $646.14.

About McKesson

McKesson Corporation provides healthcare services in the United States and internationally. It operates through four segments: U.S. Pharmaceutical, Prescription Technology Solutions (RxTS), Medical-Surgical Solutions, and International. The U.S. Pharmaceutical segment distributes branded, generic, specialty, biosimilar and over-the-counter pharmaceutical drugs, and other healthcare-related products.